Rgm Capital Trimmed Callidus Software (CALD) Holding By $1.80 Million; Papp L Roy & Associates Lowered By $591,920 Its Cvs Health (CVS) Position

December 5, 2017 - By Richard Conner

Papp L Roy & Associates decreased Cvs Health Corp (CVS) stake by 53.82% reported in 2017Q2 SEC filing. Papp L Roy & Associates sold 7,399 shares as Cvs Health Corp (CVS)’s stock declined 4.23%. The Papp L Roy & Associates holds 6,349 shares with $511,000 value, down from 13,748 last quarter. Cvs Health Corp now has $71.64B valuation. The stock decreased 1.35% or $0.97 during the last trading session, reaching $70.72. About 2.17 million shares traded. CVS Health Corporation (NYSE:CVS) has declined 24.40% since December 5, 2016 and is downtrending. It has underperformed by 41.10% the S&P500.

Rgm Capital Llc decreased Callidus Software Inc (CALD) stake by 2.73% reported in 2017Q2 SEC filing. Rgm Capital Llc sold 75,000 shares as Callidus Software Inc (CALD)’s stock rose 3.72%. The Rgm Capital Llc holds 2.67 million shares with $64.68M value, down from 2.75 million last quarter. Callidus Software Inc now has $1.84 billion valuation. The stock increased 2.28% or $0.6 during the last trading session, reaching $26.95. About 34,853 shares traded. Callidus Software Inc. (NASDAQ:CALD) has risen 22.29% since December 5, 2016 and is uptrending. It has outperformed by 5.59% the S&P500.




Since June 12, 2017, it had 0 insider purchases, and 1 insider sale for $18.44 million activity. Denton David M had sold 230,510 shares worth $18.44 million on Monday, June 12.

Papp L Roy & Associates increased Pra Health Sciences Inc stake by 9,773 shares to 28,500 valued at $2.14 million in 2017Q2. It also upped Pioneer Nat Res Co (NYSE:PXD) stake by 4,477 shares and now owns 44,119 shares. Thermo Fisher Scientific Inc (NYSE:TMO) was raised too.

Analysts await CVS Health Corporation (NYSE:CVS) to report earnings on February, 8. They expect $1.90 earnings per share, up 11.11% or $0.19 from last year’s $1.71 per share. CVS’s profit will be $1.92B for 9.31 P/E if the $1.90 EPS becomes a reality. After $1.50 actual earnings per share reported by CVS Health Corporation for the previous quarter, Wall Street now forecasts 26.67% EPS growth.

Investors sentiment decreased to 0.92 in 2017 Q2. Its down 0.17, from 1.09 in 2017Q1. It worsened, as 84 investors sold CVS shares while 559 reduced holdings. 108 funds opened positions while 483 raised stakes. 803.96 million shares or 0.96% less from 811.73 million shares in 2017Q1 were reported. Gam Hldg Ag holds 546,145 shares. Van Den Berg Mngmt I Incorporated owns 128,362 shares or 1.27% of their US portfolio. Rfg Advisory Limited Liability Corporation holds 0.15% or 6,897 shares. Gillespie Robinson & Grimm Incorporated holds 3.25% or 296,923 shares. Susquehanna Intll Gru Llp has invested 0% in CVS Health Corporation (NYSE:CVS). Pineno Levin And Ford Asset Management reported 40,793 shares or 1.55% of all its holdings. Martingale Asset Mgmt LP owns 102,618 shares. Pax World Limited Liability Corp invested 0.04% of its portfolio in CVS Health Corporation (NYSE:CVS). 7,252 are owned by Hbk Sorce Advisory Limited Company. At Bank & Trust has invested 0.22% of its portfolio in CVS Health Corporation (NYSE:CVS). Barrington Strategic Wealth Mgmt Gru Ltd Company invested in 0.66% or 16,083 shares. Optimum Inv Advsrs reported 3,444 shares stake. Kings Point Cap reported 111,523 shares. Motco has invested 0.44% in CVS Health Corporation (NYSE:CVS). Meridian Investment Counsel Inc owns 12,155 shares.

Among 25 analysts covering CVS Health (NYSE:CVS), 17 have Buy rating, 0 Sell and 8 Hold. Therefore 68% are positive. CVS Health had 57 analyst reports since July 22, 2015 according to SRatingsIntel. On Tuesday, November 7 the stock rating was maintained by Leerink Swann with “Outperform”. As per Tuesday, November 7, the company rating was maintained by Loop Capital. As per Wednesday, July 22, the company rating was maintained by Deutsche Bank. Vetr upgraded the shares of CVS in report on Monday, August 24 to “Buy” rating. The stock of CVS Health Corporation (NYSE:CVS) earned “Hold” rating by Robert W. Baird on Monday, September 25. On Monday, December 12 the stock rating was downgraded by Jefferies to “Hold”. The rating was downgraded by Robert W. Baird on Thursday, February 2 to “Neutral”. Citigroup maintained CVS Health Corporation (NYSE:CVS) rating on Monday, May 9. Citigroup has “Neutral” rating and $115 target. Citigroup maintained the shares of CVS in report on Thursday, August 17 with “Neutral” rating. JP Morgan maintained CVS Health Corporation (NYSE:CVS) on Monday, November 2 with “Overweight” rating.

Investors sentiment increased to 1.08 in Q2 2017. Its up 0.09, from 0.99 in 2017Q1. It increased, as 9 investors sold CALD shares while 52 reduced holdings. 18 funds opened positions while 48 raised stakes. 62.28 million shares or 0.06% less from 62.31 million shares in 2017Q1 were reported. Symmetry Peak Management Limited Liability Corporation has 0.05% invested in Callidus Software Inc. (NASDAQ:CALD) for 15,000 shares. Fmr Limited Company invested in 4.35M shares or 0.01% of the stock. Meeder Asset Management accumulated 39 shares. Essex Invest Management Company Ltd Liability Company holds 178,858 shares or 0.62% of its portfolio. Wasatch owns 3.24M shares. Moreover, Teton Advisors has 0.75% invested in Callidus Software Inc. (NASDAQ:CALD). Ameriprise Finance Incorporated owns 461,036 shares for 0.01% of their portfolio. First Limited Partnership stated it has 43,163 shares. Granite Investment Partners Lc holds 1.45% or 886,426 shares. Fny Managed Accounts Ltd Company has 200 shares for 0.04% of their portfolio. First Mercantile Tru owns 13,440 shares. Portolan Cap Mngmt Limited Com has 1.16M shares. Oppenheimer Comm reported 0.01% in Callidus Software Inc. (NASDAQ:CALD). Lyon Street Ltd holds 2.44% of its portfolio in Callidus Software Inc. (NASDAQ:CALD) for 250,316 shares. Arrowmark Colorado Ltd owns 3.45 million shares.

Analysts await Callidus Software Inc. (NASDAQ:CALD) to report earnings on February, 6. They expect $-0.01 earnings per share, up 83.33% or $0.05 from last year’s $-0.06 per share. After $-0.02 actual earnings per share reported by Callidus Software Inc. for the previous quarter, Wall Street now forecasts -50.00% EPS growth.

Among 11 analysts covering Callidus Software (NASDAQ:CALD), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. Callidus Software had 27 analyst reports since July 31, 2015 according to SRatingsIntel. As per Friday, August 4, the company rating was maintained by Piper Jaffray. The rating was initiated by Dougherty & Company with “Buy” on Wednesday, December 2. The stock of Callidus Software Inc. (NASDAQ:CALD) has “Buy” rating given on Thursday, June 22 by Roth Capital. The firm has “Buy” rating given on Friday, November 3 by Jefferies. Piper Jaffray reinitiated the shares of CALD in report on Friday, April 1 with “Overweight” rating. The firm has “Sell” rating given on Monday, September 19 by Dougherty & Company. Credit Suisse maintained it with “Outperform” rating and $22 target in Monday, September 19 report. The stock of Callidus Software Inc. (NASDAQ:CALD) earned “Outperform” rating by Credit Suisse on Friday, November 3. Oppenheimer maintained Callidus Software Inc. (NASDAQ:CALD) rating on Monday, September 18. Oppenheimer has “Buy” rating and $30.0 target. Piper Jaffray initiated the shares of CALD in report on Wednesday, August 26 with “Overweight” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.